You are here

Articles

Do persons with chronic myeloid leukaemia have normal or near normal survival?

Posted on Monday, January 6, 2020 - 8:27pm
https://www.nature.com/articles/s41375-019-0699-y
Read more

An investigation into the use of app technology in patients with CML.

Posted on Tuesday, November 5, 2019 - 9:30pm
An investigation into the use of app technology in patients with CML.
Read more

Cessation of nilotinib in patients with CML who have kept deep molecular responses for 2yrs

Posted on Thursday, October 3, 2019 - 12:50pm
Patients who maintained MR4.5 at 24 months of consolidation therapy proceeded to discontinuation of nilotinib.
Read more

Combining Asciminib with Ponatinib Suppresses Emergence Highly Resistant BCR-ABL1 Mutants

Posted on Thursday, October 3, 2019 - 12:42pm
We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clinical isolates and cell lines.
Read more

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic CML

Posted on Thursday, October 3, 2019 - 12:06pm
Dasatinib, a potent Bcr‐Abl tyrosine kinase inhibitor, is approved for the treatment of chronic‐phase chronic myeloid leukemia (CML‐CP) in the frontline and salvage settings.
Read more

CML: the concepts of resistance and persistence and the relationship with BCR-ABL1

Posted on Thursday, October 3, 2019 - 11:55am
Chronic myeloid leukaemia is driven by a hybrid gene, BCR-ABL1, that codes for a leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210BCR-ABL1).
Read more

Cortes Highlights Second-Generation TKIs for Frontline Therapy in CML

Posted on Friday, August 9, 2019 - 10:59am
Jorge Cortes sees the future of CML care in earlier treatments.
Read more

Video Recordings: UK Chronic Myeloid Leukaemia Patient Day 2019

Posted on Monday, July 15, 2019 - 4:46pm
Chronic Myeloid Leukaemia Patient Day Saturday, 21st September 2019, Leeds Agenda 9.30 – 10.00  Registration CML and its Treatment
Read more

CML Horizons 2019 Presentations and Video streams are available now!

Posted on Saturday, July 6, 2019 - 11:14am
Videos and PDF copies of presentations from the CML Advocates conference, 2019, are now available and can be found by following the link below:
Read more

King's College London - Patient Group (July 24th)

Posted on Saturday, June 29, 2019 - 9:21pm
CML Patient Group at King's College on 24th July 2019. Details below.
Read more

De-Escalation of TKI Therapy Before Complete Treatment Discontinuation in Patients With CML

Posted on Wednesday, June 26, 2019 - 10:42am
BACKGROUND: All studies of treatment-free remission (TFR) in patients with chronic myeloid leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have focussed on patients...
Read more

CML Horizons Conference Report: Lisbon Portugal May 17th - 19th 2019

Posted on Tuesday, May 28, 2019 - 12:26pm
CML Horizons Conference Lisbon PortugalMay 17th - 19th 2019Nigel Deekes, as the CML Support Group’s conference delegate, describes  highlights from this year’s conference.
Read more

Early results of lower dose dasatinib (50 mg daily) as frontline therapy

Posted on Wednesday, May 22, 2019 - 11:31am
Read the full text. BACKGROUND
Read more

TKI Discontinuation Criteria Established in Updated NCCN Guidelines

Posted on Wednesday, March 27, 2019 - 4:27pm
Latest NCCN guidelines for management of CML include protocols for TKI discontinuation.  Article here:
Read more

Skeletal muscle toxicity associated with TKIs in CML patients

Posted on Monday, March 18, 2019 - 3:39pm
Up to 80% of CML patients using tyrosine kinase inhibitors (TKIs) reports muscle complaints.
Read more